



# DANA CATHOLIC SMALL CAP EQUITY STRATEGY

QUARTERLY  
REVIEW

As of September 30, 2025

*The S&P 500 Index extended its rally in the third quarter of 2025, buoyed by robust corporate earnings and the Federal Reserve's long-awaited September rate cut. Market leadership once again tilted toward mega-cap stocks, though small caps, represented by the Russell 2000 Index, also participated in the rally. Despite this broad strength, lingering uncertainties—ranging from unresolved tariff disputes and their inflationary risk to the prospect of a government shutdown—still kept many investors cautious. For now, sentiment remains steady as markets adopt a “wait-and-see” approach.*

## STRATEGY PERFORMANCE

The top 5 performance contributors were Veeco Instruments Inc. (VECO), Powell Industries Inc. (POWL), Modine Manufacturing Company (MOD), Insmmed Inc. (INSM) and Installed Building Products Inc. (IBP).

Veeco Instruments delivered strong Q3 results driven by substantial orders for wet processing systems from AI and high-performance computing customers, resulting in record semiconductor segment revenue and expanded margins. Powell Industries excelled on strong execution, achieving significant gross margin improvement and a record \$1.4 billion backlog. The company continued its strategic expansion by acquiring U.K. company, Remsdaq. This acquisition enhances its automation solutions and predictive analytics capabilities for the electrical industry. Modine Manufacturing's strong Q3 was powered by double-digit sales and gross profit growth from exceptional demand for data center cooling and HVAC products, aided by the successful Scott Springfield acquisition. Biopharmaceutical company, Insmmed, continued consistent double-digit revenue growth for ARIKAYCE, as well as significant advancement of its late-stage pipeline and the anticipated brensocatib launch to treat non-cystic fibrosis bronchiectasis, a serious lung disease. Insmmed fortified its financial position after a successful secondary offering. Installed Building Products posted robust Q3 performance as revenue grew over 3% year-over-year and EPS significantly beat expectations, supported by solid demand in residential construction and favorable pricing.

The largest 5 performance detractors were Lantheus Holdings Inc. (LNTH), SPS Commerce Inc. (SPSC), Simply Good Foods Company (SMPL), TransMedics Group Inc. (TMDX), and Pinnacle Financial Partners Inc. (PNFP).

Lantheus Holdings dropped after missing Q2 EPS and revenue expectations and guiding FY EPS down significantly, citing intensified pricing pressures from competitors and anticipated contract-driven price compression into Q4. Additionally, uncertainty around the Centers for Medicare and Medicaid Services' (CMS) proposed CY26 reimbursement updates raised visibility concerns. TransMedics Group detracted from returns despite beating on Q2 revenue expectations. TransMedics' organ transplant trends are likely to require additional aircraft, potentially increasing capital expenditures and operational costs. Rising R&D also pressured margins in the near term. SPS Commerce reported slower organic growth and some headwinds related to a slower macro environment. Simply Good Foods experienced margin pressure despite its sales growth, and management did note softening growth in key brands. Pinnacle Financial reported slowing loan growth. Also, investors are skeptical of its merger with Synovus.

### Top 5 Performance Contributors <sup>a</sup> as of 09/30/2025 Quarter Return (%) (gross of fees)

Veeco Instruments Inc (VECO)	49.8
Powell Industries Inc (POWL)	45.0
Modine Manufacturing Company (MOD)	44.3
Insmmed Inc (INSM)	43.1
Installed Building Products Inc (IBP)	37.0

### Bottom 5 Performance Detractors <sup>a</sup> as of 09/30/2025 Quarter Return (%) (gross of fees)

Lantheus Holdings Inc (LNTH)	-37.3
SPS Commerce Inc (SPSC)	-23.5
Simply Good Foods Company (SMPL)	-21.4
TransMedics Group Inc (TMDX)	-16.3
Pinnacle Financial Partners Inc (PNFP)	-14.8

As measured by contribution to return, the top contributors and bottom detractors represent the best and worst performing securities held by the Strategy based on the position weight and total return of each Strategy holding. Securities are ranked by each position's Individual Performance impact on the Strategy's return for the analysis period. The contributors and detractors are listed in the order of their non-weighted total return.

## STRATEGY ACTIVITY

The Strategy added one position this quarter, Ionis Pharmaceuticals Inc. (IONS).

Ionis is a biotech company that is focused on developing RNA- and DNA-targeted medicines. The company has succeeded in obtaining FDA approvals and launching drugs that address rare genetic disorders. Ionis launched its first drug, Trimgolta, also known as Tryngolza, in 2024 to treat familial chylomicronemia syndrome (FCS). The company's second drug, Dawnzera, was launched in August 2025 and is approved to treat hereditary angioedema (HAE). Ionis Pharmaceuticals has three commercial drugs and ten more late-stage RNA-targeted therapy candidates in the pipeline, positioning the company for pioneering new treatments for rare and common diseases with significant commercial potential.

The Strategy sold Blueprint Medicines Corporation (BPMC) in the third quarter.

Blueprint Medicines is a highly specialized biotech company, focused on rare immunological diseases, with its core asset, Aivakit, being the only approved treatment for systemic mastocytosis. The company's advanced pipeline and niche expertise made it an attractive target for Sanofi S.A., enabling the latter to strengthen its immunology portfolio and deepen its presence among allergists and immunologists. This quarter Sanofi completed its acquisition of Blueprint Medicines.

## OUTLOOK

Earnings growth has remained solid this quarter, echoing last quarter's trend. That strength is tempered, however, by signs of softening in both the housing and labor markets. Against this backdrop, we remain disciplined in our approach, emphasizing relative valuation for stock selection and diversification as we move forward.

Dana Investment Advisors, Inc. ('Dana') is a SEC registered investment advisor. You should not assume that any discussion or information contained in this communication serves as the receipt of, or as a substitute for, you obtaining personalized investment advice from your own financial professional. While data contained herein was gathered from sources deemed reliable, the accuracy of the data presented herein cannot be guaranteed. Different types of investments involve varying degrees of risk, and there is no assurance that the future performance of any specific investment or investment strategy made reference to directly or indirectly in this communication, will be profitable, equal any corresponding historical performance level(s), or will continue to be suitable for your specific investment needs. In addition, due to various factors, including changing market conditions, the data contained herein may no longer be reflective of Dana's current opinions, positions, investments or client account allocations. Investing involves risks, to include the risk of loss. Investors should therefore consider consulting with an investment professional prior to making an actual investment. Please remember that past performance may not be indicative of future results. You may request additional information that is provided in the firm's ADV Part 2 Informational Brochure by either contacting Dana directly at (800) 765-0157, or by visiting the SEC's website at [www.AdviserInfo.sec.gov](http://www.AdviserInfo.sec.gov).

Strategy characteristics, allocation, contributors, detractors, top 10 holdings, style, and activity are derived from the Dana Strategy model holdings as of each period end and therefore may differ from the same criteria for the actual composite. Strategy performance data such as returns and risk are based on actual composite holdings.

Source: Dana Investment Advisors; (a) FactSet Research Systems; (b) Morningstar Direct.

Dana Investment Advisors, Inc. • 20700 Swenson Drive • Suite 400 • Waukesha, Wisconsin 53186 • P.O. Box 1067 • Brookfield, WI 53008-1067

e-mail: [Info@DanaInvestment.com](mailto:Info@DanaInvestment.com) • website: [www.DanaInvestment.com](http://www.DanaInvestment.com) • (800) 765-0157

**APPROVED FOR ADVISOR USE OR ONE-ON-ONE PRESENTATIONS ONLY**